Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985322 | 1.00 | PDPK1 (0.58) | PDPK1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL15447552 | 1.00 | PDPK1 (0.58) | PDPK1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL19521127 | 0.90 | PDPK1 (0.46) | PDPK1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL805451 | 0.86 | HTR2A (0.46) | PDPK1ACHEHTR2AHTR2CHTR2B | |
| SCHEMBL31137445 | 0.86 | PDPK1 (0.58) | PDPK1ACHESRD5A1KDM1A | |
| SCHEMBL1415389 | 0.86 | PDPK1 (0.58) | PDPK1ACHESRD5A1KDM1A | |
| SCHEMBL30850198 | 0.86 | PDPK1 (0.58) | PDPK1ACHESRD5A1KDM1A | |
| SCHEMBL23138723 | 0.80 | PDPK1 (0.59) | PDPK1ACHEHTR2CHTR2BMAOA | |
| SCHEMBL13853630 | 0.79 | MAOA (0.63) | PDPK1ACHEMAOAMAOB | |
| SCHEMBL22547382 | 0.79 | PDPK1 (0.58) | PDPK1ACHEHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2024-12-10 | — | — | US | disclosed |
| CN-118420523-A | Pyridine derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| CN-113660932-A | Phenyl derivatives with pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020205455-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS, CO., LTD. (TW) | 2020-10-08 | — | — | WO | disclosed |
| US-20200157088-A1 | BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2020-05-21 | — | — | US | disclosed |
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | PDPK1 3092/4885ACHE 2116/4885HTR2A 3852/4885 |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | PDPK1 4772/4885ACHE 1631/4885HTR2A 1813/4885 |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | AADAC, ENPP2, ATXN10 | PDPK1 2947/4885ACHE 618/4885HTR2A 1065/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | PDPK1 4772/4885ACHE 3316/4885HTR2A 2688/4885 |
| US-20200157088-A1 | BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | NR2C2, NR0B2, NR0B1 | PDPK1 4626/4885ACHE 4186/4885HTR2A 151/4885 |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | AADAC, ENPP2, ATXN10 | PDPK1 2947/4885ACHE 618/4885HTR2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.